INSIGHTS ON DRUG DEVELOPMENT

• Examining Column Reproducibility During Method Development In Clinical Labs

  In this study demonstrates how the HSS T3 stationary phase is a reliable stationary phase, as three batches made over a five-year span provide comparable results.

• Employ An icIEF-UV/MS Workflow For The Reproducible Separation Of NISTmAb Variants

  Review data that supports the reproducibility of a streamlined icIEF-UV/MS workflow for charge variant separation, UV quantitation, and peak identification of monoclonal antibodies (mAbs) by coupling two systems.

• Establishing A Robust Workflow To Identify High-Performing Clones

  Cell line development is a complex, labor intensive, and multistep process. Learn about a platform and host cell line that minimize the risk and timeline to develop high-performing clones.

• Optimization Of A Two-Step Purification Method For Bispecific Antibodies

  Explore the further development of a two-step purification of a bispecific antibody (bsAb) in a collaborative study to develop a downstream process.

• Optimized And Scalable LNP Composition For RNA Vaccine Delivery

  12/20/2023

  Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications.

• Advancing Precision Medicine With Patient-On-A-Chip

  3/8/2024

  Emulate and Cedars-Sinai Medical Center have partnered to develop a Patient-on-a-Chip program that combines their stem cell expertise and Organs-on-Chips technology to advance precision medicine.

• SPR Assays To The Assess Similarity Between Innovator And Biosimilar Versions of Nivolumab (Opdivo®)

  9/2/2022

  Learn more about developed and qualified SPR assays to characterize the binding and affinity of biosimilar and innovator nivolumab for all seven Fc gamma receptors, FcRn and PD-1.

   

• Pursuing Venture Philanthropy With Opus Genetics: The Business Of Biotech

  8/10/2022

  Explore new, more agile approaches to overcoming the advanced therapy obstacles inherent to bringing rare disease treatments to market.

• What Is A Viral Vector?

  4/16/2024

  Review a novel adenovirus production process that offers scalable, single-use equipment-compatible solutions, reducing production time and cross-contamination risks.